Thermo Fisher Scientific Inc. $TMO Shares Bought by Russell Investments Group Ltd.

Russell Investments Group Ltd. grew its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 3.9% in the third quarter, Holdings Channel reports. The firm owned 351,042 shares of the medical research company’s stock after purchasing an additional 13,133 shares during the period. Russell Investments Group Ltd.’s holdings in Thermo Fisher Scientific were worth $237,133,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of TMO. Allspring Global Investments Holdings LLC increased its stake in shares of Thermo Fisher Scientific by 9.7% during the third quarter. Allspring Global Investments Holdings LLC now owns 140,228 shares of the medical research company’s stock valued at $91,500,000 after buying an additional 12,414 shares during the period. Leelyn Smith LLC lifted its stake in Thermo Fisher Scientific by 0.8% in the third quarter. Leelyn Smith LLC now owns 9,789 shares of the medical research company’s stock worth $6,608,000 after acquiring an additional 77 shares during the period. Parallel Advisors LLC boosted its holdings in Thermo Fisher Scientific by 0.4% in the third quarter. Parallel Advisors LLC now owns 37,831 shares of the medical research company’s stock valued at $25,538,000 after acquiring an additional 137 shares in the last quarter. Mader & Shannon Wealth Management Inc. increased its position in Thermo Fisher Scientific by 1.7% during the 3rd quarter. Mader & Shannon Wealth Management Inc. now owns 18,775 shares of the medical research company’s stock valued at $12,674,000 after purchasing an additional 316 shares during the period. Finally, International Assets Investment Management LLC raised its holdings in Thermo Fisher Scientific by 3,023.3% in the 3rd quarter. International Assets Investment Management LLC now owns 170,000 shares of the medical research company’s stock worth $114,758,000 after purchasing an additional 164,557 shares in the last quarter. 89.23% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

TMO has been the topic of several research reports. Evercore dropped their price target on Thermo Fisher Scientific from $720.00 to $615.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 28th. Morgan Stanley raised their price objective on Thermo Fisher Scientific from $650.00 to $730.00 and gave the company an “overweight” rating in a research report on Monday, October 12th. Barclays boosted their target price on shares of Thermo Fisher Scientific from $750.00 to $775.00 and gave the company an “overweight” rating in a report on Thursday, October 22nd. Jefferies Financial Group reaffirmed a “buy” rating and issued a $630.00 target price (up from $585.00) on shares of Thermo Fisher Scientific in a research report on Thursday, July 23rd. Finally, TD Cowen increased their price target on shares of Thermo Fisher Scientific from $760.00 to $810.00 and gave the stock a “buy” rating in a research note on Thursday, October 22nd. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $683.64.

Thermo Fisher Scientific Stock Performance

Shares of NYSE TMO opened at $699.55 on Friday. The firm’s 50-day moving average price is $669.20 and its 200-day moving average price is $556.44. Thermo Fisher Scientific Inc. has a 52-week low of $435.27 and a 52-week high of $727.56. The company has a market cap of $259.20 billion, a PE ratio of 29.03, a PEG ratio of 2.92 and a beta of 0.84. The company has a quick ratio of 1.41, a current ratio of 1.81 and a debt-to-equity ratio of 0.71.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, October 21st. The medical research company reported $6.68 earnings per share for the quarter, beating the consensus estimate of $6.40 by $0.28. The firm had revenue of $12.14 billion for the quarter, compared to analysts’ expectations of $11.95 billion. Thermo Fisher Scientific had a return on equity of 17.33% and a net margin of 14.94%. The company’s revenue was up 9.1% compared to the same quarter last year. During the same period in the prior year, the firm earned $5.79 EPS. As a group, analysts anticipate that Thermo Fisher Scientific Inc. will post 25.27 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, January 15th. Shareholders of record on Tuesday, December 15th will be issued a dividend of $0.47 per share. The ex-dividend date of this dividend is Tuesday, December 15th. This represents a $1.88 annualized dividend and a yield of 0.3%. Thermo Fisher Scientific’s payout ratio is currently 9.92%.

Latest Thermo Fisher Scientific News

These are some of the TMO news items that stood out recently:

• Positive Sentiment: A report discusses Thermo Fisher’s $5 billion buyback, putting its cash generation and capital returns in focus. Repurchases can support per-share results and signal confidence, though the article also questions whether cash flows justify expectations after the stock’s strong multiyear return. Is Thermo Fisher Scientific Reasonable After Its $5 Billion Buyback?
• Positive Sentiment: Coverage highlights Thermo Fisher as a supplier to cell-sheet gene-therapy developers, extending its relevance in regenerative medicine. This could create opportunities as the field develops, although the article does not quantify near-term revenue impact. Thermo Fisher Scientific, Why Is It Back In The Spotlight?
• Neutral Sentiment: Industry reports project growth in markets where Thermo Fisher competes, including single-use bioprocessing, cell lysis and cell-culture coatings. These forecasts suggest favorable longer-term demand, but are broad market estimates—not evidence of new orders or a change in the company’s outlook. Single-Use Bioprocessing Market Report

Insider Buying and Selling

In related news, VP Lisa Britt sold 11,440 shares of the company’s stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $613.12, for a total value of $7,014,092.80. Following the completion of the transaction, the vice president owned 14,784 shares of the company’s stock, valued at approximately $9,064,366.08. This represents a 43.62% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Marc Casper sold 10,000 shares of the company’s stock in a transaction dated Thursday, August 20th. The stock was sold at an average price of $629.27, for a total value of $6,292,700.00. Following the completion of the transaction, the chief executive officer directly owned 123,925 shares of the company’s stock, valued at approximately $77,982,284.75. This trade represents a 7.47% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 24,546 shares of company stock valued at $15,479,192. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific develops and supplies products and services used in scientific research, clinical diagnostics, and pharmaceutical and biotechnology manufacturing. Its offerings include laboratory instruments, reagents and consumables, analytical equipment, diagnostic tests, and services that support drug development and clinical research. The company operates through businesses focused on life sciences, analytical instruments, specialty diagnostics, and laboratory products and biopharma services.